Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
4 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
Pearl Toh, 3 days ago
Quadrivalent human papillomavirus (HPV) vaccination can substantially reduce the risk of invasive cervical cancer, by up to almost 90 percent in women who were vaccinated early, a large Swedish registry-based study has shown.

CASPIAN: Durvalumab + platinum-etoposide improves OS in ES-SCLC

Elaine Soliven
05 Dec 2019
Dr Makoto Nishio

First-line treatment with durvalumab + platinum-etoposide (EP)* improves overall survival (OS) in Asian patients with extensive-stage small-cell lung cancer (ES-SCLC), according to the CASPIAN** study.

The 76 Asian patients (from Japan [n=34], South Korea [n=28], Taiwan [12], and China [n=2]) with ES-SCLC in this randomized, open-label, phase III trial were randomized to receive either durvalumab 1,500 mg + EP intravenously Q3W for four cycles and continued every 4 weeks until disease progression or EP alone intravenously Q3W for six cycles, followed by an optional prophylactic cranial irradiation as per the investigator’s discretion. [ESMO Asia 2019, abstract LBA15]

In a prespecified exploratory analysis, the OS rate at 12 months was greater among patients who received durvalumab + EP compared with those on EP alone (63.7 percent vs 49.5 percent).

Compared with EP alone, Asian patients treated with durvalumab + EP also had a higher median OS (14.8 vs 11.9 months; hazard ratio [HR], 0.87, 95 percent confidence interval [CI], 0.45–1.64), which was consistent with the global population (median, 13.0 vs 10.3 months; HR, 0.73, 95 percent CI, 0.59–0.91).

“[However], interpretation of OS in the Asia subgroup is limited due to small numbers of patients,” said Dr Makoto Nishio from the Department of Thoracic Medical Oncology at the Cancer Institute Hospital of Japanese Foundation for Cancer Research in Tokyo, Japan.

Constipation (45.7 percent vs 46.2 percent), nausea (42.9 percent vs 46.2 percent), and neutropenia (37.1 percent vs 48.7 percent) were the most common adverse events (AEs) reported in the durvalumab + EP and EP-only treatment arms.

Grade 3 or 4 AEs were more frequent in patients treated with EP alone compared with durvalumab + EP (76.9 percent vs 62.9 percent). Serious AEs occurred in 19 patients in the EP-alone arm and 15 patients in the durvalumab + EP arm. One AE event leading to death was reported in the durvalumab + EP arm.

Immune-mediated AEs of any grade occurred in 20 percent of patients, but only one patient in the durvalumab + EP arm reported a grade 3 or 4 immune-mediated AE and one patient had type 1 diabetes.

“The safety profile of durvalumab + EP in this Asian subgroup was consistent with the known safety profile of durvalumab and EP, and was generally consistent with the global population,” Nishio noted.

“Combining durvalumab with either cisplatin- or carboplatin-etoposide in ES-SCLC provides an important new treatment option for patients and physicians,” he concluded.

 

*EP: Etoposide 80–100 mg/m2 with either carboplatin AUC 5–6 or cisplatin 75–80 mg/m2

**CASPIAN: Durvalumab ± tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
4 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
Pearl Toh, 3 days ago
Quadrivalent human papillomavirus (HPV) vaccination can substantially reduce the risk of invasive cervical cancer, by up to almost 90 percent in women who were vaccinated early, a large Swedish registry-based study has shown.